CINGW and CING Related Headlines
Go Back- Cingulate closes $12 million private placement at market price
- Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Cingulate appoints Bryan Downey as chief commercial officer
- Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
- Cingulate reports positive phase 3 trial results for ADHD drug CTx-1301
- Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
- Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
- FDA accepts Cingulate's drug application for ADHD treatment CTx-1301
- FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
- Cingulate secures exclusive US manufacturing deal for ADHD treatment
- Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
- Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
- Cingulate places CEO on administrative leave, names interim leadership
- Cingulate Provides Management Team Update
- Cingulate submits FDA application for ADHD drug CTx-1301
- Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
- Cingulate receives $4.3 million FDA fee waiver for ADHD drug application
- Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
- Cingulate names Nilay Patel as chief legal officer ahead of FDA filing
- Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application
CINGW and CING Related Press Releases
Go Back- Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
- Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
- Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
- FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
- Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
- Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
- Cingulate Provides Management Team Update
- Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
- Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
- Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application
